Home LiteratureArticle Details
PMID: 21150330 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions.

Cell cycle (Georgetown, Tex.) ·Vol. 9 ·No. 24 ·2010-12-15 ·Pages 4824-35

Wang HW, Joyce JA

Abstract

Although macrophages were originally recognized as major immune effector cells, it is now appreciated that they also play many important roles in the maintenance of tissue homeostasis, and are involved in a variety of pathological conditions including cancer. Several studies have demonstrated the contributions of tumor-associated macrophages (TAMs) to tumor initiation, progression, and metastasis. However, the detailed mechanisms underlying how TAMs differ molecularly from their normal counterparts and how the conversion to TAMs occurs have only just begun to be understood. TAMs have been proposed to exhibit phenotypes of 'alternatively activated' macrophages, though there has been limited evidence directly linking the phenotypes of TAMs to the alternative activation of macrophages. This review will focus on IL-4, the prototypic cytokine that induces the alternative activation of macrophages, and review current knowledge regarding the contributions of IL-4 to the phenotypes of TAMs and its effects on tumorigenesis.

MeSH Terms
Animals Cathepsins/metabolism Cytokines/immunology Disease Progression Humans Interleukin-4/immunology Macrophages/immunology,physiology Neoplasms/immunology,pathology Phenotype Signal Transduction/immunology
Chemicals
Cytokines Interleukin-4 Cathepsins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Wang Hao-Wei
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Cornell University, New York, NY, USA.
Joyce Johanna A
References (141)
141 references, click to expand
  1. The chemokine system in diverse forms of macrophage activation and polarization.
    Trends Immunol. 2004 Dec;25(12):677-86 PMID: 15530839
  2. The IL-4 receptor: signaling mechanisms and biologic functions.
    Annu Rev Immunol. 1999;17:701-38 PMID: 10358772
  3. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins.
    J Immunol. 2004 May 1;172(9):5467-77 PMID: 15100288
  4. Nitric oxide as a secretory product of mammalian cells.
    FASEB J. 1992 Sep;6(12):3051-64 PMID: 1381691
  5. IL-4/IL-13 signaling beyond JAK/STAT.
    J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1063-70 PMID: 10856136
  6. Nitric oxide and the immune response.
    Nat Immunol. 2001 Oct;2(10):907-16 PMID: 11577346
  7. Multinucleated giant cells.
    Curr Opin Hematol. 2000 Jan;7(1):40-7 PMID: 10608503
  8. Novel biological functions of interleukin-4: formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo.
    Biochem Biophys Res Commun. 1998 Sep 18;250(2):444-8 PMID: 9753649
  9. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3.
    Scand J Immunol. 2001 Apr;53(4):386-92 PMID: 11285119
  10. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis.
    Genes Dev. 2006 Mar 1;20(5):543-56 PMID: 16481467
  11. Structure, binding, and antagonists in the IL-4/IL-13 receptor system.
    Biochim Biophys Acta. 2002 Nov 11;1592(3):237-50 PMID: 12421669
  12. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B.
    J Biol Chem. 2001 Dec 21;276(51):47771-4 PMID: 11694501
  13. Nitric oxide and macrophage function.
    Annu Rev Immunol. 1997;15:323-50 PMID: 9143691
  14. Inhibition of angiogenesis by interleukin 4.
    J Exp Med. 1998 Sep 21;188(6):1039-46 PMID: 9743522
  15. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis.
    Clin Cancer Res. 2009 Oct 1;15(19):6042-51 PMID: 19789302
  16. Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter.
    BMC Mol Biol. 2006 Nov 29;7:45 PMID: 17134490
  17. The scavenger receptor CD36 plays a role in cytokine-induced macrophage fusion.
    J Cell Sci. 2009 Feb 15;122(Pt 4):453-9 PMID: 19155290
  18. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.
    J Natl Cancer Inst. 2010 Apr 21;102(8):522-8 PMID: 20233997
  19. Cysteine cathepsin proteases as pharmacological targets in cancer.
    Trends Pharmacol Sci. 2008 Jan;29(1):22-8 PMID: 18037508
  20. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors.
    Am J Pathol. 2009 Mar;174(3):1048-64 PMID: 19218341
  21. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors.
    J Immunol. 1998 Jan 1;160(1):345-50 PMID: 9551990
  22. A clonal culture system demonstrates that IL-4 induces a subpopulation of noncytolytic T cells with low CD8, perforin, and granzyme expression.
    J Immunol. 2002 Feb 15;168(4):1672-81 PMID: 11823496
  23. The macrophage: past, present and future.
    Eur J Immunol. 2007 Nov;37 Suppl 1:S9-17 PMID: 17972350
  24. Murine interleukin-4 displays potent anti-tumor activity in vivo.
    Cell. 1989 May 5;57(3):503-12 PMID: 2785856
  25. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.
    Cancer Cell. 2009 Aug 4;16(2):91-102 PMID: 19647220
  26. Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer.
    Biol Chem. 2010 Aug;391(8):937-45 PMID: 20731543
  27. Interleukin-4 inhibits the vascular endothelial growth factor- and basic fibroblast growth factor-induced angiogenesis in vitro.
    Mol Cells. 2002 Aug 31;14(1):115-21 PMID: 12243340
  28. Tumor rejection by modulation of tumor stromal fibroblasts.
    J Exp Med. 2003 Nov 17;198(10):1487-93 PMID: 14623905
  29. Macrophage diversity enhances tumor progression and metastasis.
    Cell. 2010 Apr 2;141(1):39-51 PMID: 20371344
  30. How are T(H)2-type immune responses initiated and amplified?
    Nat Rev Immunol. 2010 Apr;10(4):225-35 PMID: 20336151
  31. Murine macrophages cultured with IL-4 acquire a phenotype similar to that of epithelioid cells from granulomatous inflammation.
    Inflammation. 2003 Aug;27(4):201-11 PMID: 14527173
  32. Lysosomal cysteine proteases: facts and opportunities.
    EMBO J. 2001 Sep 3;20(17):4629-33 PMID: 11532926
  33. Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidylinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3.
    J Immunol. 2007 Jun 1;178(11):6886-93 PMID: 17513737
  34. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.
    Science. 1992 Jul 24;257(5069):548-51 PMID: 1636093
  35. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.
    J Immunol. 2000 Dec 1;165(11):6024-8 PMID: 11086033
  36. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer.
    Cancer Res. 2006 May 15;66(10):5242-50 PMID: 16707449
  37. Spontaneously formed tumorigenic hybrids of Meth A sarcoma cells and macrophages in vivo.
    Int J Cancer. 2003 Aug 20;106(2):153-9 PMID: 12800188
  38. THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCE.
    J Exp Med. 1964 Jul 1;120:105-20 PMID: 14194388
  39. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4).
    J Immunol. 1987 Mar 15;138(6):1813-6 PMID: 3493289
  40. IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.
    Cancer Immunol Immunother. 2006 Oct;55(10):1228-37 PMID: 16810557
  41. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.
    Science. 1991 Nov 1;254(5032):713-6 PMID: 1948050
  42. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis.
    Cancer Res. 2008 Nov 1;68(21):8687-94 PMID: 18974110
  43. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study.
    J Immunother. 2002 Jul-Aug;25(4):352-8 PMID: 12142558
  44. Interleukin-4 and interleukin-13 signaling connections maps.
    Science. 2003 Jun 6;300(5625):1527-8 PMID: 12791978
  45. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.
    Cancer Cell. 2004 May;5(5):443-53 PMID: 15144952
  46. Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages.
    J Immunol. 2002 Feb 15;168(4):1911-8 PMID: 11823526
  47. IL-4 promotes the formation of multinucleated giant cells from macrophage precursors by a STAT6-dependent, homotypic mechanism: contribution of E-cadherin.
    J Leukoc Biol. 2007 Dec;82(6):1542-53 PMID: 17855502
  48. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions.
    Br J Cancer. 2005 Mar 14;92(5):921-8 PMID: 15714203
  49. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells.
    J Immunol. 2005 Jun 1;174(11):6561; author reply 6561-2 PMID: 15905489
  50. Cysteine cathepsins and the cutting edge of cancer invasion.
    Cell Cycle. 2007 Jan 1;6(1):60-4 PMID: 17245112
  51. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation.
    J Exp Med. 1992 Jul 1;176(1):287-92 PMID: 1613462
  52. Tumour-cell fusion as a source of myeloid traits in cancer.
    Lancet Oncol. 2005 Dec;6(12):988-93 PMID: 16321767
  53. Macrophage fusion: the making of osteoclasts and giant cells.
    J Exp Med. 2005 Aug 1;202(3):337-40 PMID: 16061722
  54. Blood monocytes consist of two principal subsets with distinct migratory properties.
    Immunity. 2003 Jul;19(1):71-82 PMID: 12871640
  55. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors.
    J Biol Chem. 2006 Mar 3;281(9):6020-9 PMID: 16365041
  56. Exploring the full spectrum of macrophage activation.
    Nat Rev Immunol. 2008 Dec;8(12):958-69 PMID: 19029990
  57. Cysteine cathepsins: multifunctional enzymes in cancer.
    Nat Rev Cancer. 2006 Oct;6(10):764-75 PMID: 16990854
  58. Alternative activation of macrophages.
    Nat Rev Immunol. 2003 Jan;3(1):23-35 PMID: 12511873
  59. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.
    Cell. 2006 Jan 27;124(2):263-6 PMID: 16439202
  60. Alternative activation of macrophages: an immunologic functional perspective.
    Annu Rev Immunol. 2009;27:451-83 PMID: 19105661
  61. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo.
    J Immunol. 2008 May 1;180(9):6270-8 PMID: 18424750
  62. The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth?
    Tissue Antigens. 2007 Apr;69(4):293-8 PMID: 17389011
  63. Role for interleukin-4 in foreign-body giant cell formation on a poly(etherurethane urea) in vivo.
    J Biomed Mater Res. 1995 Oct;29(10):1267-75 PMID: 8557729
  64. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
    Clin Cancer Res. 2002 Nov;8(11):3503-11 PMID: 12429641
  65. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.
    J Immunol. 1994 Dec 15;153(12):5659-73 PMID: 7989764
  66. Role of IL-4 and IFN-gamma in Schistosoma mansoni egg-induced hypersensitivity granuloma formation. Orchestration, relative contribution, and relationship to macrophage function.
    J Immunol. 1992 Feb 1;148(3):900-6 PMID: 1309844
  67. Divergent effects of interleukin-4 and interferon-gamma on macrophage-derived chemokine production: an amplification circuit of polarized T helper 2 responses.
    Blood. 1998 Oct 15;92(8):2668-71 PMID: 9763548
  68. Microenvironmental regulation of metastasis.
    Nat Rev Cancer. 2009 Apr;9(4):239-52 PMID: 19279573
  69. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice.
    Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2497-502 PMID: 20133781
  70. Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes.
    Blood. 2009 Nov 19;114(21):4664-74 PMID: 19726720
  71. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression.
    J Immunol. 2006 Nov 15;177(10):7303-11 PMID: 17082649
  72. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study.
    J Immunother. 1998 Nov;21(6):440-6 PMID: 9807739
  73. Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions.
    Blood. 2006 Jul 15;108(2):575-83 PMID: 16556895
  74. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein.
    Int J Cancer. 1994 Aug 15;58(4):574-81 PMID: 8056454
  75. Paradoxical roles of IL-4 in tumor immunity.
    Cell Mol Immunol. 2009 Dec;6(6):415-22 PMID: 20003817
  76. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.
    Genes Dev. 2010 Feb 1;24(3):241-55 PMID: 20080943
  77. Nomenclature of monocytes and dendritic cells in blood.
    Blood. 2010 Oct 21;116(16):e74-80 PMID: 20628149
  78. A review of studies on targeting interleukin 4 receptor for central nervous system malignancy.
    Curr Mol Med. 2009 Aug;9(6):732-9 PMID: 19689300
  79. Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway.
    FASEB J. 2007 May;21(7):1433-44 PMID: 17283223
  80. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
    Trends Immunol. 2002 Nov;23(11):549-55 PMID: 12401408
  81. Identification of a T cell-derived b cell growth factor distinct from interleukin 2.
    J Exp Med. 1982 Mar 1;155(3):914-23 PMID: 6977612
  82. Interleukin-4 acts as a potent stimulator for expression of monocyte chemoattractant JE/MCP-1 in mouse peritoneal macrophages.
    Biochem Biophys Res Commun. 1994 Aug 30;203(1):562-9 PMID: 8074704
  83. Th1 and Th2 cytokines cooperate to stimulate mannose-receptor-mediated phagocytosis.
    J Leukoc Biol. 1998 Jul;64(1):108-13 PMID: 9665284
  84. Melanoma x macrophage hybrids with enhanced metastatic potential.
    Clin Exp Metastasis. 1998 May;16(4):299-312 PMID: 9626809
  85. Chemokines: immunology's high impact factors.
    Nat Immunol. 2001 Feb;2(2):95-101 PMID: 11175800
  86. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4.
    Cell Death Differ. 2008 Apr;15(4):762-72 PMID: 18202702
  87. Macrophage activation and polarization.
    Front Biosci. 2008 Jan 01;13:453-61 PMID: 17981560
  88. Mechanisms of phagocytosis in macrophages.
    Annu Rev Immunol. 1999;17:593-623 PMID: 10358769
  89. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.
    Blood. 2008 Nov 15;112(10):4098-108 PMID: 18716132
  90. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.
    J Neurooncol. 2003 Oct;65(1):15-25 PMID: 14649882
  91. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).
    Blood. 2006 Mar 1;107(5):2112-22 PMID: 16269622
  92. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.
    J Immunol. 2006 Apr 15;176(8):5023-32 PMID: 16585599
  93. Interleukin 4 induces cultured monocytes/macrophages to form giant multinucleated cells.
    J Exp Med. 1988 Feb 1;167(2):598-611 PMID: 3258008
  94. The molecular basis of macrophage fusion.
    Immunobiology. 2007;212(9-10):785-93 PMID: 18086379
  95. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells.
    Bull World Health Organ. 1972;46(6):845-52 PMID: 4538544
  96. Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities.
    Proc Natl Acad Sci U S A. 1986 Aug;83(16):5894-8 PMID: 3016727
  97. STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells.
    Neoplasia. 2002 Jul-Aug;4(4):324-31 PMID: 12082548
  98. The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13.
    J Immunol. 2000 Sep 1;165(5):2818-23 PMID: 10946314
  99. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity.
    J Immunol. 2005 Jun 1;174(11):7194-201 PMID: 15905564
  100. Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells.
    J Immunol. 1988 Jan 15;140(2):456-64 PMID: 2961813
  101. M-1/M-2 macrophages and the Th1/Th2 paradigm.
    J Immunol. 2000 Jun 15;164(12):6166-73 PMID: 10843666
  102. IFN-gamma and IL-4 differently regulate inducible NO synthase gene expression through IRF-1 modulation.
    Int Immunol. 2000 Jul;12(7):977-85 PMID: 10882409
  103. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene.
    J Exp Med. 1996 Apr 1;183(4):1323-9 PMID: 8666890
  104. Interleukin-4-induced macrophage fusion is prevented by inhibitors of mannose receptor activity.
    Am J Pathol. 1996 Sep;149(3):975-85 PMID: 8780401
  105. Macrophage fusion induced by IL-4 alternative activation is a multistage process involving multiple target molecules.
    Eur J Immunol. 2007 Jan;37(1):33-42 PMID: 17154265
  106. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
    J Immunol. 2002 Nov 15;169(10):5796-804 PMID: 12421960
  107. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.
    J Immunol. 2000 Dec 1;165(11):6015-9 PMID: 11086031
  108. Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells.
    J Immunol. 2003 Feb 15;170(4):2014-21 PMID: 12574371
  109. Progressive differentiation and commitment of CD8+ T cells to a poorly cytolytic CD8low phenotype in the presence of IL-4.
    J Immunol. 2005 Feb 15;174(4):2021-9 PMID: 15699131
  110. Interleukin-4 impairs granzyme-mediated cytotoxicity of Simian virus 40 large tumor antigen-specific CTL in BALB/c mice.
    Cancer Immunol Immunother. 2007 Oct;56(10):1625-36 PMID: 17431618
  111. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines.
    Eur J Immunol. 1997 Sep;27(9):2375-82 PMID: 9341783
  112. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
    Cancer Res. 2007 Oct 15;67(20):9903-12 PMID: 17942922
  113. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
    J Immunol. 2001 Jun 1;166(11):6500-8 PMID: 11359800
  114. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
    Mol Cell Biol. 1992 Mar;12(3):954-61 PMID: 1312220
  115. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.
    Nature. 1985 May 9-15;315(6015):115-22 PMID: 2986015
  116. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.
    Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2774-8 PMID: 8464888
  117. Type 1 and type 2 cytokine regulation of macrophage endocytosis: differential activation by IL-4/IL-13 as opposed to IFN-gamma or IL-10.
    J Immunol. 1999 Apr 15;162(8):4606-13 PMID: 10202000
  118. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase.
    Nature. 1999 Jul 22;400(6742):378-82 PMID: 10432118
  119. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism.
    J Exp Med. 1999 Mar 15;189(6):919-30 PMID: 10075975
  120. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.
    Cancer Res. 2004 Oct 1;64(19):7022-9 PMID: 15466195
  121. Cysteine cathepsins in human cancer.
    Biol Chem. 2004 Nov;385(11):1017-27 PMID: 15576321
  122. Monocyte and macrophage heterogeneity.
    Nat Rev Immunol. 2005 Dec;5(12):953-64 PMID: 16322748
  123. Epithelial interleukin-4 receptor expression promotes colon tumor growth.
    Carcinogenesis. 2010 Jun;31(6):1010-7 PMID: 20176658
  124. Blood monocytes: development, heterogeneity, and relationship with dendritic cells.
    Annu Rev Immunol. 2009;27:669-92 PMID: 19132917
  125. The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium.
    Int J Cancer. 1997 Aug 7;72(4):664-72 PMID: 9259408
  126. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype.
    BMC Immunol. 2002 Jul 04;3:7 PMID: 12098359
  127. Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages: characterization and evidence for receptor recycling.
    Cell. 1980 Jan;19(1):207-15 PMID: 6766809
  128. TH2 cytokines and allergic challenge induce Ym1 expression in macrophages by a STAT6-dependent mechanism.
    J Biol Chem. 2002 Nov 8;277(45):42821-9 PMID: 12215441
  129. Chemical approaches for functionally probing the proteome.
    Mol Cell Proteomics. 2002 Jan;1(1):60-8 PMID: 12096141
  130. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages.
    Biochem Biophys Res Commun. 1995 Jan 17;206(2):667-73 PMID: 7530004
  131. Suppressor of cytokine signaling-1 is an IL-4-inducible gene in macrophages and feedback inhibits IL-4 signaling.
    Genes Immun. 2007 Jan;8(1):21-7 PMID: 17093501
  132. Signaling mechanisms, interaction partners, and target genes of STAT6.
    Cytokine Growth Factor Rev. 2006 Jun;17(3):173-88 PMID: 16540365
  133. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
    Mol Med. 2000 Mar;6(3):165-78 PMID: 10965493
  134. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.
    Cell Stem Cell. 2007 Oct 11;1(4):389-402 PMID: 18371377
  135. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells.
    J Exp Med. 2005 Aug 1;202(3):345-51 PMID: 16061724
  136. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    J Immunol. 2001 Dec 1;167(11):6497-502 PMID: 11714817
  137. Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion.
    Blood. 2010 Jan 14;115(2):353-62 PMID: 19880493
  138. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
    Int J Cancer. 2008 Dec 15;123(12):2915-22 PMID: 18798553
  139. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells.
    Cancer Res. 2006 Feb 1;66(3):1491-9 PMID: 16452205
  140. The mannose receptor is a pattern recognition receptor involved in host defense.
    Curr Opin Immunol. 1998 Feb;10(1):50-5 PMID: 9523111
  141. The inflammatory chemokines CCL2 and CCL5 in breast cancer.
    Cancer Lett. 2008 Aug 28;267(2):271-85 PMID: 18439751
Article Info
Journal
Cell cycle (Georgetown, Tex.)
Abbr.
Cell Cycle
ISSN
1551-4005
DOI
10.4161/cc.9.24.14322
Published
2010-12-15
Epub
2010-00-15
Pages
4824-35
Language
English
Region
United States
NLM ID
101137841
PMCID
PMC3047808
Subset
IM
External Links
PubMed source DOI: 10.4161/cc.9.24.14322 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2